[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 18, 1926


Author Affiliations

From the Department of Biochemistry, University of Alberta Faculty of Medicine.

JAMA. 1926;87(12):908-910. doi:10.1001/jama.1926.02680120018005

The preparation of a stable, physiologically standardized extract containing the active principle of the parathyroid glands is a matter of such recent date that it is impossible at this time to designate with any degree of finality the therapeutic value of the new hormone.1

The experimental work in the laboratory has, it is true, gone ahead very rapidly, and it may be definitely stated from the results of this work that the active parathyroid extract is a specific for experimental parathyroid tetany in the same sense that insulin is a specific in experimental diabetes.

With this essential fact established, it was safe to predict that the new preparation would be a specific in hypoparathyroidism in the human subject. Clinical results thus far available entirely justify this view; that is to say, in hypoparathyroidism in the human subject the parathyroid hormone has been shown to be a specific remedial agent.

First Page Preview View Large
First page PDF preview
First page PDF preview